<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04090151</url>
  </required_header>
  <id_info>
    <org_study_id>The RESPOND Outcomes Study</org_study_id>
    <nct_id>NCT04090151</nct_id>
  </id_info>
  <brief_title>The RESPOND Outcomes Study</brief_title>
  <official_title>The RESPOND Outcomes Study - A Study in the RESPOND Consortium (RESPOND: International Cohort Consortium of Infectious Diseases)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The RESPOND Outcomes study is a research study around use of antiretroviral and other
      relevant drugs and long-term clinical outcomes in patients living with HIV. Data collected in
      this study will be used to answer key unanswered questions regarding treatment of people
      living with HIV.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The specific objectives, falling into three main categories, are as follows:

        1. Monitor the uptake of newer antiretroviral treatment (ART) drugs and drugs for treatment
           of co-infections and co-morbidities;

        2. To evaluate the safety profiles of the newer individual ART drugs when used in routine
           clinical practice as part of either first-line or subsequent treatment regimens.

        3. Investigate long term outcomes and clinical disease progression overall and in specific
           sub-groups

      The Outcomes study is a collaboration between investigators from clinics and cohorts across
      Europe, Australia and South America with a willingness to share data and to use a common
      follow-up schedule and assessment. Participating sites have a commitment to continue to
      follow this large cohort that is heterogeneous in both its demographic profile and in ART
      prescribing patterns thus resulting in enough power to answer many key clinical questions.

      The Outcomes study is a study in the RESPOND International Cohort Consortium of Infectious
      Diseases. RESPOND is an innovative, flexible and dynamic cohort consortium for the study of
      infectious diseases, including HIV, built as a generic structure for facilitating multi
      stakeholder involvement. In RESPOND all collected data is part of a common data repository or
      'data lake', which is stored in a database located at CHIP, Rigshospitalet, Copenhagen,
      Denmark. Data collection in RESPOND is modular with a core data collection module onto which
      additional modules/studies can be added. Pseudonymised patient data can be entered manually
      via an online secure platform or be electronically transferred from existing local, regional
      or national data structures to the data lake.

      In the Outcomes study data will be collected at enrolment and at annual follow-up (FU)
      visits. For patients living with HIV-1 enrolled and under FU, demographic, laboratory,
      therapeutic and clinical data on HIV and viral hepatitis will be collected once a year.
      Clinical event data (except AIDS other than AIDS defining malignancies) will be collected in
      real-time on RESPOND event forms.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>8 Years</target_duration>
  <primary_outcome>
    <measure>Proportion of HIV positive persons who initiate treatment with newer antiretroviral drugs</measure>
    <time_frame>From date of enrolment until the date of progression, lost to follow-up or death, whichever comes first, assessed up to 6 years</time_frame>
    <description>Proportion of HIV positive persons who initiate treatment with newer antiretroviral drugs and to describe changes over time in use of specific antiretroviral drugs in individual countries and diverse demographic groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of HIV positive persons who initiate treatment of co-infections</measure>
    <time_frame>From date of enrolment until the date of progression, lost to follow-up or death, whichever comes first, assessed up to 6 years</time_frame>
    <description>Proportion of HIV positive persons who initiate treatment of co-infections and to describe changes over time in individual countries and diverse demographic groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of HIV positive persons who initiate treatment of co-morbidities</measure>
    <time_frame>From date of enrolment until the date of progression, lost to follow-up or death, whichever comes first, assessed up to 6 years</time_frame>
    <description>Proportion of HIV positive persons who initiate treatment of co-morbidities and to describe changes over time in individual countries and diverse demographic groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Monitor changes in plasma CD4+ T-lymphocyte counts among persons exposed to newer individual ARVs</measure>
    <time_frame>From date of enrolment until the date of progression, lost to follow-up or death, whichever comes first, assessed up to 6 years</time_frame>
    <description>Monitor changes in plasma CD4+ T-lymphocyte counts among persons exposed to newer individual ARVs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Monitor plasma HIV-RNA responses among persons exposed to newer individual ARVs</measure>
    <time_frame>From date of enrolment until the date of progression, lost to follow-up or death, whichever comes first, assessed up to 6 years</time_frame>
    <description>Monitor plasma HIV-RNA responses among persons exposed to newer individual ARVs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the short- and long-term adverse effects of the newer ARVs when used in routine clinical practice</measure>
    <time_frame>From date of enrolment until the date of progression, lost to follow-up or death, whichever comes first, assessed up to 6 years</time_frame>
    <description>Evaluate the short- and long-term adverse effects of the newer ARVs when used in routine clinical practice as part of either first-line or subsequent treatment regimens, and whether adverse effects are reversible on discontinuation of the offending ARVs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Investigate if adverse effects are increased in some patient sub-groups in order to build clinical risk prediction scores to aid effective strategies for risk reduction</measure>
    <time_frame>From date of enrolment until the date of progression, lost to follow-up or death, whichever comes first, assessed up to 6 years</time_frame>
    <description>Investigate if adverse effects are increased in some patient sub-groups (e.g. those defined by age, gender, ethnicity, HIV-risk group, viral hepatitis- TB and other co-infections, ongoing viremia and across CD4 count strata) in order to build clinical risk prediction scores to aid effective strategies for risk reduction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Investigate if adverse effects are increased in some patient sub-groups in order to assess the risk and benefit for the individual</measure>
    <time_frame>From date of enrolment until the date of progression, lost to follow-up or death, whichever comes first, assessed up to 6 years</time_frame>
    <description>Investigate if adverse effects are increased in some patient sub-groups (e.g. those defined by age, gender, ethnicity, HIV-risk group, viral hepatitis- TB and other co-infections, ongoing viremia and across CD4 count strata) in order to assess the risk and benefit for the individual of any antiretroviral or group of antiretrovirals</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Investigate long term clinical outcomes and clinical disease progression overall and in specific sub-groups</measure>
    <time_frame>From date of enrolment until the date of progression, lost to follow-up or death, whichever comes first, assessed up to 6 years</time_frame>
    <description>Investigate long term clinical outcomes and clinical disease progression overall and in specific sub-groups (e.g. those defined by age, gender, ethnicity, HIV-risk group, viral hepatitis- TB and other co-infections, ongoing viremia and across CD4 count strata)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Develop predictive risk-scores for the development of clinical outcomes to enable personalized decisions regarding risk and benefit of specific treatments in different demographic groups</measure>
    <time_frame>From date of enrolment until the date of progression, lost to follow-up or death, whichever comes first, assessed up to 6 years</time_frame>
    <description>After investigating long term clinical outcomes and clinical disease progression overall and in specific sub-groups (e.g. those defined by age, gender, ethnicity, HIV-risk group, viral hepatitis- TB and other co-infections, ongoing viremia and across CD4 count strata): to develop predictive risk-scores for the development and outcomes to enable personalized decisions regarding risk and benefit of specific treatments in different demographic groups</description>
  </primary_outcome>
  <number_of_groups>17</number_of_groups>
  <enrollment type="Anticipated">37853</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Austrian HIV Cohort Study (AHIVCOS)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>The Australian HIV Observational Database (AHOD)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>CHU Saint-Pierre</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>University Hospital Cologne</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>The EuroSIDA cohort</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Frankfurt HIV Cohort Study</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Georgian National AIDS Health Information System (AIDS HIS)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Modena HIV Cohort</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>San Raffaele Scientific Institute</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Swiss HIV Cohort Study (SHCS)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Royal Free HIV Cohort Study</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>The ATHENA national observational HIV cohort</arm_group_label>
    <description>ATHENA: AIDS Therapy Evaluation in the Netherlands</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nice HIV Cohort</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Italian Cohort Naive Antiretrovirals (ICONA)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>PISCIS Cohort Study</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Swedish InfCare HIV Cohort</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Bonn University Hospital</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Participating clinics will enrol eligible persons living with HIV. Some clinics will enrol
        all their eligible persons living with HIV, and others will enrol a random sample.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed Informed consent for the Outcomes study, if required by local/national
             legislation

          2. Signed informed consent for the RESPOND consortium and data repository, if required by
             local/national legislation

          3. Age ≥ 18 years of age

          4. Confirmed HIV-1 infection

          5. Persons receiving integrase inhibitor (INSTI) based antiretroviral therapy if have
             started after the later of 1/1/2012 and local cohort enrolment (i.e., during
             prospective follow-up in the cohort and after 1/1/2012) and have a CD4 and HIV viral
             load in the 12 months prior to starting INSTI or within 3 months after starting INSTI.

          6. ART experienced and ART naïve persons not receiving INSTI if have a CD4 and HIV viral
             load in the 12 months prior to baseline or within 3 months after baseline (here, the
             latest of 1/1/2012 or cohort enrolment).

          7. Persons lost to follow-up or who died before RESPOND enrolment should therefore still
             be included in the Outcomes study, provided they satisfy the other inclusion criteria.

        Exclusion Criteria:

          1. Persons receiving INSTI before 1/1/2012 are excluded from the Outcome study

          2. Persons aged &lt; 18 at baseline are excluded from the Outcome study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lars Peters, MD</last_name>
    <phone>+45 35 45 57 64</phone>
    <email>lars.peters@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Australian HIV Observational Database (AHOD)</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Petoumenos, Associate Professor</last_name>
      <phone>+61 (0)2 9385 0900</phone>
      <email>kpetoumenos@kirby.unsw.edu.au</email>
    </contact>
    <investigator>
      <last_name>Matthew Law, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Austrian HIV Cohort Study (AHIVCOS), Medizinische Universität Innsbruch</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Zangerle, MD</last_name>
      <email>robert.zangerle@tirol-kliniken.at</email>
    </contact>
    <investigator>
      <last_name>Robert Zangerle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Saint-Pierre Hospital</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathan Glumeck</last_name>
      <email>infectiousdiseases@stpierre-bru.be</email>
    </contact>
    <investigator>
      <last_name>Stéphane De Wit</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars Peters, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The EuroSIDA Study, CHIP, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars Peters, MD</last_name>
      <phone>+45 35451501</phone>
      <email>Lars.Peters@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Gilles Wandeler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nice HIV Cohort, Centre Hospitalier Universitaire de Nice</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Pradier, Prof</last_name>
      <email>pradier.c@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Christian Pradier, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgian National AIDS Health Information System (AIDS HIS), IDACIRC</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikoloz Chkhartishvili, MD</last_name>
      <email>nc@aidscenter.ge</email>
    </contact>
    <investigator>
      <last_name>Nikoloz Chkhartishvili, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan-Christian Wasmuth, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jan-Christian Wasmuth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Cologne</name>
      <address>
        <city>Cologne</city>
        <zip>5093</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerd Fätkenheuer, Prof</last_name>
      <email>g.faetkenheuer@uni-koeln.de</email>
    </contact>
    <investigator>
      <last_name>Jörg Janne Vehreschild, Prog</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Frankfurt HIV Cohort Study, Goethe-University Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>60323</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Stephan, Prof</last_name>
      <email>Christoph.Stephan@hivcenter.de</email>
    </contact>
    <investigator>
      <last_name>Christoph Stephan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Italian Cohort Naive Antiretrovirals (ICONA)</name>
      <address>
        <city>Milano</city>
        <zip>20124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonella d'Arminio Monforte, Prof</last_name>
      <email>antonella.darminio@unimi.it</email>
    </contact>
    <investigator>
      <last_name>Antonella d'Arminio Monforte, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Raffaele Scientific Institute, Ospedale San Raffaele</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adriano Lazzarin, Prof</last_name>
      <email>lazzarin.adriano@hsr.it</email>
    </contact>
    <investigator>
      <last_name>Adriano Lazzarin, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonella Castagna, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Modena HIV Cohort, Università degli Studi di Modena</name>
      <address>
        <city>Modena</city>
        <zip>44100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Mussini, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>crimuss@unimore.it</last_name>
    </contact_backup>
    <investigator>
      <last_name>Cristina Mussini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The ATHENA (AIDS Therapy Evaluation in the Netherlands) national observational HIV cohort, Stichting HIV Monitorin, AMC, University of Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Reiss, Prof</last_name>
      <email>p.reiss@amc.uva.nl</email>
    </contact>
    <investigator>
      <last_name>Ferdinand Wit, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PISCIS Cohort Study, Germans Trias i Pujol University Hospital</name>
      <address>
        <city>Badalona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreu Bruguera, MD</last_name>
      <phone>+34 93 497 88 91</phone>
      <email>ceeiscat@iconcologia.net</email>
    </contact>
    <investigator>
      <last_name>Jordi Casabona, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Josep Miró, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish InfCare HIV Cohort, Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anders Sönnerborg, Prof</last_name>
      <email>anders.sonnerborg@ki.se</email>
    </contact>
    <investigator>
      <last_name>Anders Sönnerborg, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swiss HIV Cohort Study (SHCS), University Hospital Zurich</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huldrych Günthard, MD</last_name>
      <email>huldrych.guenthard@usz.ch</email>
    </contact>
    <investigator>
      <last_name>Huldrych Günthard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Free HIV Cohort Study, Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2 PF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret Johnson, Prof</last_name>
      <email>a.johnson@ucl.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Colette Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://chip.dk/Studies/RESPOND</url>
    <description>The RESPOND Study</description>
  </link>
  <results_reference>
    <citation>Obel N, Omland LH, Kronborg G, Larsen CS, Pedersen C, Pedersen G, Sørensen HT, Gerstoft J. Impact of non-HIV and HIV risk factors on survival in HIV-infected patients on HAART: a population-based nationwide cohort study. PLoS One. 2011;6(7):e22698. doi: 10.1371/journal.pone.0022698. Epub 2011 Jul 25.</citation>
    <PMID>21799935</PMID>
  </results_reference>
  <results_reference>
    <citation>Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, Kowalska JD, de Wit S, Law M, el Sadr W, Kirk O, Friis-Moller N, Monforte Ad, Phillips AN, Sabin CA, Lundgren JD; D:A:D Study Group. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet. 2014 Jul 19;384(9939):241-8. doi: 10.1016/S0140-6736(14)60604-8.</citation>
    <PMID>25042234</PMID>
  </results_reference>
  <results_reference>
    <citation>Schouten J, Wit FW, Stolte IG, Kootstra NA, van der Valk M, Geerlings SE, Prins M, Reiss P; AGEhIV Cohort Study Group. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis. 2014 Dec 15;59(12):1787-97. doi: 10.1093/cid/ciu701. Epub 2014 Sep 2.</citation>
    <PMID>25182245</PMID>
  </results_reference>
  <results_reference>
    <citation>Chary A, Nguyen NN, Maiton K, Holodniy M. A review of drug-drug interactions in older HIV-infected patients. Expert Rev Clin Pharmacol. 2017 Dec;10(12):1329-1352. doi: 10.1080/17512433.2017.1377610. Epub 2017 Sep 19. Review.</citation>
    <PMID>28922979</PMID>
  </results_reference>
  <results_reference>
    <citation>Weber R, Sabin CA, Friis-Møller N, Reiss P, El-Sadr WM, Kirk O, Dabis F, Law MG, Pradier C, De Wit S, Akerlund B, Calvo G, Monforte Ad, Rickenbach M, Ledergerber B, Phillips AN, Lundgren JD. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med. 2006 Aug 14-28;166(15):1632-41.</citation>
    <PMID>16908797</PMID>
  </results_reference>
  <results_reference>
    <citation>Kattakuzhy S, Gross C, Emmanuel B, Teferi G, Jenkins V, Silk R, Akoth E, Thomas A, Ahmed C, Espinosa M, Price A, Rosenthal E, Tang L, Wilson E, Bentzen S, Masur H, Kottilil S; and the ASCEND Providers. Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers: A Nonrandomized Clinical Trial. Ann Intern Med. 2017 Sep 5;167(5):311-318. doi: 10.7326/M17-0118. Epub 2017 Aug 8.</citation>
    <PMID>28785771</PMID>
  </results_reference>
  <results_reference>
    <citation>Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS. Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review. Ann Intern Med. 2017 May 2;166(9):637-648. doi: 10.7326/M16-2575. Epub 2017 Mar 21. Review.</citation>
    <PMID>28319996</PMID>
  </results_reference>
  <results_reference>
    <citation>van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Heathcote EJ, Manns MP, Kuske L, Zeuzem S, Hofmann WP, de Knegt RJ, Hansen BE, Janssen HL. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012 Dec 26;308(24):2584-93. doi: 10.1001/jama.2012.144878.</citation>
    <PMID>23268517</PMID>
  </results_reference>
  <results_reference>
    <citation>Friis-Møller N, Ryom L, Smith C, Weber R, Reiss P, Dabis F, De Wit S, Monforte AD, Kirk O, Fontas E, Sabin C, Phillips A, Lundgren J, Law M; D:A:D study group. An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study. Eur J Prev Cardiol. 2016 Jan;23(2):214-23. doi: 10.1177/2047487315579291. Epub 2015 Apr 16.</citation>
    <PMID>25882821</PMID>
  </results_reference>
  <results_reference>
    <citation>Mocroft A, Lundgren JD, Ross M, Fux CA, Reiss P, Moranne O, Morlat P, Monforte Ad, Kirk O, Ryom L; Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) Study. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study. Lancet HIV. 2016 Jan;3(1):e23-32. doi: 10.1016/S2352-3018(15)00211-8. Epub 2015 Nov 17.</citation>
    <PMID>26762990</PMID>
  </results_reference>
  <results_reference>
    <citation>Bruyand M, Ryom L, Shepherd L, Fatkenheuer G, Grulich A, Reiss P, de Wit S, D Arminio Monforte A, Furrer H, Pradier C, Lundgren J, Sabin C; D:A:D study group. Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: the D: A: D study. J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):568-77. doi: 10.1097/QAI.0000000000000523.</citation>
    <PMID>25763785</PMID>
  </results_reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 30, 2019</study_first_submitted>
  <study_first_submitted_qc>September 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2019</study_first_posted>
  <last_update_submitted>September 16, 2019</last_update_submitted>
  <last_update_submitted_qc>September 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Jens D Lundgren, MD</investigator_full_name>
    <investigator_title>MD, DMSc Professor, Rigshospitalet &amp; University of Copenhagen, Director, CHIP - Centre of Excellence for Health, Immunity and Infections</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Prospective</keyword>
  <keyword>Cohort</keyword>
  <keyword>HCV</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

